Department of Urology, Kyungpook National University School of Medicine, Daegu, Korea.
Investig Clin Urol. 2017 Mar;58(2):127-133. doi: 10.4111/icu.2017.58.2.127. Epub 2017 Jan 25.
We investigated the efficacy and safety of a readjustable midurethral sling (Remeex system) for stress urinary incontinence with female voiding dysfunction.
From May 2007 to December 2015, 151 women received the Remeex system. We excluded patients who presented with pelvic organ prolapse and/or who missed the regular follow-up. Finally, 102 patients were included in the study, and we divided them into 2 groups: group A (n=74), who did not present with female voiding dysfunction and group B (n=28), who presented with female voiding dysfunction. Female voiding dysfunction was defined as a maximal flow rate≤12 mL/s when the voided volume was ≥150 mL on preoperative uroflowmetry. We retrospectively reviewed the patients' medical records and compared surgical outcomes between groups A and B.
There were no significant differences in subjective surgical outcomes and patient satisfaction between the 2 groups. Postoperative uroflowmetry showed that the maximal flow rate and voided volume decreased and the postvoid residual urine volume increased in both groups, and these changes were not significantly different between groups. The overall complication rate was 21.6% (22 of 102), and the complication rate was not significantly different between the 2 groups according to the modified Clavien-Dindo classification.
The Remeex system is efficacious and safe for stress urinary incontinence with female voiding dysfunction.
我们研究了可调式中段尿道吊带(Remeex 系统)治疗女性排尿功能障碍伴压力性尿失禁的疗效和安全性。
自 2007 年 5 月至 2015 年 12 月,共 151 例女性患者接受了 Remeex 系统治疗。我们排除了合并盆腔器官脱垂和/或失访的患者。最终,102 例患者纳入本研究,并将其分为 2 组:A 组(n=74),无女性排尿功能障碍;B 组(n=28),有女性排尿功能障碍。女性排尿功能障碍定义为术前尿流率测定时,尿量≥150ml 时最大尿流率≤12ml/s。我们回顾性分析了患者的病历资料,并比较了 A 组和 B 组的手术结果。
两组患者的主观手术效果和患者满意度无显著差异。术后尿流率显示,两组最大尿流率和尿量均降低,残余尿量增加,但组间差异无统计学意义。总并发症发生率为 21.6%(102 例中有 22 例),根据改良 Clavien-Dindo 分级,两组的并发症发生率无显著差异。
Remeex 系统治疗女性排尿功能障碍伴压力性尿失禁安全有效。